These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Hosotani H; Ohashi Y; Yamada M; Tsubota K Am J Ophthalmol; 1995 Mar; 119(3):288-94. PubMed ID: 7872388 [TBL] [Abstract][Full Text] [Related]
8. Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats. Hosotani H; Ohashi Y; Kinoshita S; Matsumoto T; Awata T Curr Eye Res; 1996 Oct; 15(10):1005-7. PubMed ID: 8921238 [TBL] [Abstract][Full Text] [Related]
9. A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients. Nakahara M; Miyata K; Otani S; Miyai T; Nejima R; Yamagami S; Amano S Br J Ophthalmol; 2005 Mar; 89(3):266-8. PubMed ID: 15722300 [TBL] [Abstract][Full Text] [Related]
10. Aldose reductase inhibitor counteracts the enhanced expression of matrix metalloproteinase-10 and improves corneal wound healing in galactose-fed rats. Takamura Y; Matsumoto T; Tomomatsu T; Matsumura T; Takihara Y; Inatani M Mol Vis; 2013; 19():2477-86. PubMed ID: 24339723 [TBL] [Abstract][Full Text] [Related]
11. Aldose reductase inhibition prevents galactose-induced ovarian dysfunction in the Sprague-Dawley rat. Meyer WR; Doyle MB; Grifo JA; Lipetz KJ; Oates PJ; DeCherney AH; Diamond MP Am J Obstet Gynecol; 1992 Dec; 167(6):1837-43. PubMed ID: 1471707 [TBL] [Abstract][Full Text] [Related]
12. Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy. Ohashi Y; Matsuda M; Hosotani H; Tano Y; Ishimoto I; Fukuda M; Manabe R Am J Ophthalmol; 1988 Mar; 105(3):233-8. PubMed ID: 3125744 [TBL] [Abstract][Full Text] [Related]
13. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Frank RN; Amin R; Kennedy A; Hohman TC Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227 [TBL] [Abstract][Full Text] [Related]
14. Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor. Obrosova I; Faller A; Burgan J; Ostrow E; Williamson JR Curr Eye Res; 1997 Jan; 16(1):34-43. PubMed ID: 9043821 [TBL] [Abstract][Full Text] [Related]
15. The effect of aldose reductase inhibitor on the corneal epithelium. Tsubota K; Yamada M Cornea; 1993 Mar; 12(2):161-2. PubMed ID: 8500324 [TBL] [Abstract][Full Text] [Related]
16. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs. Datiles MB; Kador PF; Kashima K; Kinoshita JH; Sinha A Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2201-4. PubMed ID: 2122961 [TBL] [Abstract][Full Text] [Related]
17. Permeability of the blood-retinal and blood-aqueous barriers in galactose-fed rats. Caspers-Velu LE; Wadhwani KC; Rapoport SI; Kador PF J Ocul Pharmacol Ther; 1995; 11(3):469-87. PubMed ID: 8590278 [TBL] [Abstract][Full Text] [Related]
18. Effects of seven days of galactose feeding and aldose reductase inhibition on mast cells and vessel morphometry in rat sciatic nerve. Brett FM; Kalichman MW; Calcutt NA; Mizisin AP J Neurol Sci; 1996 Sep; 141(1-2):6-12. PubMed ID: 8880685 [TBL] [Abstract][Full Text] [Related]